Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Rogelio Solis / AP
At least 400,000 Americans have multiple sclerosis, and they are paying too much for their drugs to treat the condition, according to a new report from the Institute for Clinical and Economic Review.
ICER, a not-for-profit group that the pharmaceutical industry loathes, attempts to identify the cost effectiveness of drugs. Many of the multiple sclerosis drugs ICER studied are clinically effective. But the group's president, Dr. Steven Pearson, said in a statement that "high prices and regular price increases contribute significantly to restrictions on coverage and access that make it difficult for patients to get the medications they need." Multiple sclerosis drugs cost between $63,000 per year and more than $100,000 per year.
Companies in the crosshairs that make multiple sclerosis drugs: AbbVie, Bayer, Biogen, Genentech, Merck, Novartis, Sanofi, and Teva Pharmaceutical Industries.